AstraZeneca targets $1.5 billion in annual cuts over three years, reinvesting savings in R&D
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
AstraZeneca has launched a three-year cost-cutting program aimed at saving $1.5 billion per year, with those savings reinvested in research and development, Pharmaphorum reports. The company has not said how many jobs may be affected. It expects a one-time cost to implement the initiative.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu